CTRI/2016/11/007451招募中3 期
Bladder Cancer Adjuvant Radiotherapy Trial - BART
Tata Memorial Centre Department of Atomic Energy Clinical Trial Centre0 个研究点目标入组 153 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 153
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All patients should have undergone radical cystoprostatectomy for bladder cancer
- •Patients with any of the below high risk features on histolopathology
- •1.Lymph Node positive with or without
- •perinodal extension (PNE)
- •2.Cut-margin positive,
- •3.pT3 and pT4 disease,
- •4.Number of nodes dissected at surgery < 10
- •All patients irrespective of the final pathology if they have received neo-adjuvant chemotherapy prior to surgery for any of the following
- •T3 T4 stage
- •N1-3 stage
- •No evidence of distant metastasis including para-aortic nodal metastasis
- •KPS >= 70
排除标准
- •oContraindication to pelvic radiotherapy like inflammatory bowel disease
- •oUncontrolled diabetes or hypertension
- •oUncontrolled cardiac or respiratory co morbidity
- •oPrior history of therapeutic irradiation to pelvis
- •oPatient unwilling and unreliable for follow up and QoL
研究者
相似试验
尚未招募
1 期
Bladder Adaptive Radiotherapy (BART) Trial - A study on the feasibility of BART.Bladder CancerACTRN12613000774729Royal Prince Alfred Hospital20
进行中（未招募）
不适用
Phase II Studie: Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom - BevXelOx-RTPatienten mit lokal fortgeschrittenem Rektumkarzinom im Klinischen Stadium II/IIIEUCTR2007-001558-21-DEniversitätsklinikum Schleswig-Holstein
Unknown
不适用
Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder CancerHigh-Risk CancerUrothelial Carcinoma BladderNCT04740866Cairo University100
招募中
不适用
ERUPT Trial: Urethral scarring after radiation treatment for prostate cancerProstate CancerACTRN12619000971134Icon Cancer Foundation350
尚未招募
2 期
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder CancerBladder CancerNCT06310369European Organisation for Research and Treatment of Cancer - EORTC50